

Oncology Today with Dr Neil Love: Management of Paroxysmal Nocturnal Hemoglobinuria

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes the mechanism of action of iptacopan?
 - a. Selective factor B inhibitor
 - b. C3 convertase inhibitor
 - c. C5 inhibitor
 - d. C6/7 inhibitor

2. Approximately what percentage of patients receiving iptacopan for previously untreated paroxysmal nocturnal hemoglobinuria (PNH) on the Phase III APPOINT trial achieved transfusion independence by week 24?
 - a. 20%
 - b. 40%
 - c. 65%
 - d. Greater than 90%

3. Which of the following best describes the mechanism of action of danicopan?
 - a. Selective factor B inhibitor
 - b. Factor D inhibitor
 - c. C5 inhibitor
 - d. C6/7 inhibitor

4. Clinical trial evidence supports that eculizumab reduces which of the following events in patients with PNH?
 - a. Hemolysis
 - b. Thrombotic events
 - c. Need for transfusions
 - d. Fatigue
 - e. All of the above

5. Which of the following procedures should be performed prior to treatment with the anti-C5 antibodies eculizumab and ravulizumab?
 - a. Cardiac stress test
 - b. Meningococcal vaccination
 - c. Neurological examination
 - d. Ophthalmic examination